Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World’s leading Event Organizer


4th Asia-Pacific Global Summit & Expo on Healthcare

Brisbane, Australia

Keerti Jain

Keerti Jain

National Institute of Pharmaceutical Education and Research, India

Title: Dendrimers: Anti-angiogenic nanomaterials for treatment of cancer


Biography: Keerti Jain


Formation of new blood vessels from pre-existing blood vessels i.e. angiogenesis play crucial role in the metastasis and growth of tumor, and hence inhibition of neo-vascularization could be a lucrative approach in the successful treatment of cancer. Numerous preclinical investigational studies showed that the combined treatment of cancer with angiogenesis and chemotherapy/radiotherapy could result in improved outcomes as compared to chemotherapy and/or radiotherapy. In this regard we could postulate that the designing of a nano-material with anti-angiogenic activity and potential to deliver anticancer drug selectively to cancer cells may emerge as a promising therapeutic approach for treatment of cancer. Dendrimers represent a well defined three-dimensional macromolecular structure synthesized in a step-wise controlled manner with nearly mono-disperse polymeric architecture. Some dendrimer molecules including poly-L-lysine (PLL) dendrimers, poly-arginine dendrimers with glycine core, poly(propylene imine) (PPI) dendrimers with surface arginine groups have shown intrinsic anti-angiogenic activity in previous reports including from our laboratory. Particularly PLL dendrimers have been investigated thoroughly for anti-angiogenic activity and showed reduced vascularization, significant reduction in apoptosis/necrosis of tumor tissue and moderate regression effect on tumor growth equivalent to commercially available antiangiogenic agent, Avastin (anti-VEGF antibody bevacizumab) without significant toxic effect on non-cancerous tissues. In this presentation I will enlighten the progress made in design of anti-angiogenic dendrimers, dendrimers as nano-carrier for delivery of anticancer drugs and future possibilities to improve treatment strategies for cancer via two pronged attack on cancer with anti-angiogenic dendrimers and chemotherapeutic agents including reports from our laboratory and other laboratories as well.